<DOC>
	<DOCNO>NCT02692677</DOCNO>
	<brief_summary>The purpose study assess absorption , metabolism , excretion JNJ-42756493 healthy male adult participant administration single oral dose 12 milligram ( mg ) unlabeled JNJ-42756493 admix 14C JNJ-42756493 .</brief_summary>
	<brief_title>A Study Assess Absorption , Metabolism , Routes Excretion Following Oral Administration ( 14C ) Radiolabeled JNJ -- 42756493 Healthy Male Participants</brief_title>
	<detailed_description>This single -- center , open -- label ( The researcher participant know treatment participant receive ) study . The study consist 3 part : Screening ( 35 day ) , Open-label Treatment Phase ( Day 1 Day 14 28 ) Í¾ Follow-up ( 30 day ) . Total duration study approximately 79 93 day . Plasma urine collect determination JNJ-42756493 concentration . Participants primarily evaluate absorption , metabolic pathway excretion JNJ-42756493 . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Willing adhere prohibition restriction specify protocol A man sexually active must agree use condom ; man sexually active woman childbearing potential vasectomy , must agree use condom combination adequate contraception method deem appropriate investigator ( example , doublebarrier method , partner use effective contraception [ define hormonal contraception ( pill , patch , injection ) , intrauterine device , surgical sterilization ] donate sperm 5 month receive study drug Body mass index ( BMI ; weight [ kg ] /height2 [ ] 2 ) 18 30 kilogram per square meter ( kg/m2 ) ( inclusive ) , body weight less 50 kg History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency [ creatinine clearance 90 milliliter per minute ( mL/min ) ] , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result History current evidence ophthalmic disorder , central serous retinopathy retinal vein occlusion , active wet age relate macular degeneration , diabetic retinopathy macular edema , uncontrolled glaucoma , corneal pathology keratitis , keratoconjunctivitis , keratopathy , corneal abrasion , inflammation ulceration Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) clinically significant abnormal value hematology , clinical chemistry , urinalysis screen screen admission study center deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 14 day dose schedule EndofStudy procedure History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 5 year screen positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , benzodiazepine ) screen Day 2 treatment period .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42756493</keyword>
</DOC>